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Recombinant human parainfluenza virus type 1 (HPIV1) and mutants containing point and deletion (Δ) mutations in the P/C gene
(r-CΔ10–15HNT553A, r-CR84G, r-CF170S and r-CΔ170), which have previously been evaluated as HPIV1 vaccine candidates, were evaluated for their
effect on the type I interferon (IFN) response in vitro. HPIV1 wt infection inhibited the IFN response by inhibiting IFN regulatory factor-3 (IRF-3)
activation and IFN production inA549 cells and IFN signaling in Vero cells. In contrast, r-CR84G, r-CF170S and r-CΔ170 were defective for inhibition of
IRF-3 activation and IFN production and r-CF170S and r-CΔ170 did not inhibit IFN signaling. Thus, HPIV1 antagonizes the IFN response at both the
level of induction and signaling, and antagonism at both levels was disrupted by mutations in the P/C gene. Because CF170S affects C and not P, the
anti-IFN function can be attributed to the C proteins. These data, in the context of previous in vivo studies, suggest that the loss of antagonism of the
IFN response at both the level of induction and signaling, observed with the P/C mutants, r-CF170S and r-CΔ170, was necessary for significant
attenuation in African green monkeys (AGMs).
Published by Elsevier Inc.Keywords: Human parainfluenza virus; Interferon antagonist; Attenuating mutation; Vaccine candidateIntroduction
Human parainfluenza virus type 1 (HPIV1) is a member of
the Paramyxoviridae family of viruses, which encompasses a
group of significant human pathogens including respiratory
syncytial virus (RSV), HPIV2, HPIV3, measles virus, mumps
virus and the recently identified human metapneumovirus
(HMPV) (Chanock et al., 2001; van den Hoogen et al., 2001).
The human parainfluenza viruses belong to the subfamily Para-
myxovirinae and are further classified into the genera Respir-
ovirus (HPIV1 and HPIV3) and Rubulavirus (HPIV2 and
HPIV4). HPIV1, HPIV2 and HPIV3 cause significant respira-⁎ Corresponding author. Fax: +1 301 480 1268.
E-mail address: EBartlett@niaid.nih.gov (E.J. Bartlett).
0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2006.04.011tory disease in infants and young children, accounting for 6.0%,
3.2% and 11.5%, respectively, of pediatric hospitalizations due
to respiratory disease, making them collectively the second
leading cause of pediatric hospitalizations for respiratory disease
behind RSV (Chanock et al., 2001; Murphy et al., 1988). Para-
influenza viruses are also becoming increasingly recognized as
causes of respiratory disease in adults and immunocompromised
patients (Atmar et al., 1998; Cortez et al., 2001; Fiore et al.,
1998; Jokinen et al., 2001; Lewis et al., 1996; Marx et al., 1999).
Clinical manifestations range from mild disease, including
rhinitis, pharyngitis and otitis media, to severe disease, including
croup, bronchiolitis and pneumonia (Chanock et al., 2001;
Counihan et al., 2001; Heikkinen et al., 1999; Henderson et al.,
1982; Marx et al., 1997; Reed et al., 1997). A licensed vaccine is
not available for the prevention of HPIV illness in humans.
62 W. Van Cleve et al. / Virology 352 (2006) 61–73HPIV1 is an enveloped, negative sense, non-segmented,
single-stranded RNA virus with a genome length of 15,600
nucleotides, containing six genes in the order 3′-N-P/C-M-F-
HN-L-5′. The genome encodes three nucleocapsid-associated
proteins, namely, the nucleoprotein (N), the phosphoprotein (P)
and the large polymerase (L); three envelope-associated pro-
teins, namely, the internal matrix protein (M) and the fusion (F)
and hemagglutinin-neuraminidase (HN) transmembrane surface
glycoproteins; and four related accessory proteins encoded by
the C gene, namely, C′, C, Y1 and Y2 (Chanock et al., 2001).
Each HPIV1 gene encodes a single protein with the exception of
the P/C gene, which contains two open reading frames (ORFs),
one coding for P and one coding for the C proteins. The C
proteins initiate at four separate translational start codons and are
carboxy co-terminal. Expression of the Y2 protein, whose exist-
ence is predicted based on the nucleotide sequence and by
analogy to Sendai virus (SeV, murine PIV1), has not been
directly confirmed for HPIV1 (Power et al., 1992). C proteins are
expressed by viruses of the Respirovirus, Morbillivirus and
Henipahvirus genera, but not by viruses of the Rubulavirus and
Avulavirus genera. The C proteins of SeV, the most extensively
studied member of the Respirovirus genus and the closest
homolog of HPIV1, have multiple functions, including roles as
interferon (IFN) antagonists (Garcin et al., 2003; Gotoh et al.,
2003; Komatsu et al., 2004).
Live attenuated intranasal virus vaccines for HPIV1 are being
developed using reverse genetics, and several mutations in the P/
C gene have been developed for use in vaccine candidates
(Bartlett et al., 2005; McAuliffe et al., 2004; Newman et al.,
2002, 2004). We previously reported that a Phe to Ser sub-
stitution at amino acid residue 170 in the C protein of HPIV1,
designated CF170S, and a deletion of amino acids 169 and 170 in
C, designated CΔ170, attenuated HPIV1 for rodents and African
green monkeys (AGMs) (Bartlett et al., 2006; Newman et al.,
2004). The CF170S mutation was originally identified in SeV as
an attenuating mutation for mice (Itoh et al., 1997). In addition,
the CR84G/HNT553A set of mutations attenuated HPIV1 for
AGMs but not hamsters, an effect that depends on the presence
of both mutations and probably reflects the sum of two inde-
pendent weakly attenuating mutations (Bartlett et al., 2005). The
mutant rCR84G, which is examined in the present study, lacks the
mutation in HN and was not attenuated in AGMs. In contrast, a
deletion of amino acids 10–15 of the C protein of HPIV1,
designated CΔ10–15, which attenuated SeV for mice (Garcin et
al., 2002), restricted replication of HPIV1 in hamsters but not in
AGMs. Because the C proteins of SeV are IFN antagonist
proteins, which are involved in decreasing both the production
of IFN-β and the signaling of IFN through its receptor (Garcin et
al., 2003; Gotoh et al., 2003; Komatsu et al., 2004), and because
viruses with loss of anti-IFN functions are generally attenuated
in vivo (Conzelmann, 2005), the attenuation and host-range
phenotypes associated with the HPIV1 C protein mutations
might involve effects on the host IFN response.
In the present study, the sensitivity of HPIV1 to the antiviral
activity of IFN-β and IFN-α, and the production of IFNs in
response to infection of human cells with recombinant HPIV1s
(rHPIV1s) were determined. In addition, the ability of HPIV1 wtand mutant viruses to interfere with the induction of an antiviral
state by exogenous IFN was studied to assess whether the
HPIV1 mutant viruses modify the signaling of IFN through its
receptor. This analysis correlated the effects of the PIV1 muta-
tions in C on the IFN system in vitro with the attenuation in
AGMs demonstrated in previous studies, which also identified
residues that are involved in species-specific effects (Bartlett et
al., 2006). This provides an understanding of the basis for
attenuation by several mutations that have been developed for
inclusion in live attenuated HPIV1 vaccine candidates being
developed by reverse genetics.
Results
Sensitivity of replication of rHPIV1 wt (r-wt) and mutants to
IFN-α and -β
The mutations present in the recombinant P/C viruses in-
cluded in this study, namely, r-CΔ10–15, r-CR84G, r-CF170S and r-
CΔ170, and their attenuation phenotype in hamsters and AGMs
(Bartlett et al., 2005, 2006; Newman et al., 2002) are sum-
marized in Table 1. It is noteworthy that r-CF170S affects amino
acid coding only in the C proteins, that is, there is no mutation in
the P protein that is encoded by the overlapping ORF, and
therefore any alteration in phenotype of r-CF170S can be solely
ascribed to the mutation in C. In contrast, each of the other
mutations in C also affected amino acid coding in the over-
lapping P ORF (Table 1). Also note that the r-CR84G is not
attenuated in AGMs. A virus that is not included in the present
study, r-CR84GHNT553A virus, was attenuated in the upper res-
piratory tract (URT) of AGMs, a phenotype that depends on the
presence of both mutations (Bartlett et al., 2005). However,
because we were mainly interested in the effect of the R84G
amino acid substitution on C protein function, the r-CR84G virus
lacking the HNT553A mutation was evaluated here. Complete
genomic sequence analysis indicated that each of the viruses in
Table 1 contains only the mutations listed with the exception of
the r-CΔ10–15, which also contains (i) a Thr to Ala amino acid
substitution at codon 553 in the HN protein, HNT553A, and (ii) a
single adventitious point mutation in the P/C gene that creates a
Glu to Lys substitution at codon 17 in C and an Arg to Glu at
codon 20 in P (Bartlett et al., 2006). However, as will be shown
below, the r-CΔ10–15 virus did not significantly inhibit the IFN
system in primate cells, making the issue of possible contribu-
tions of adventitious mutations irrelevant.
We first sought to examine whether the difference in atte-
nuation of r-wt, r-CF170S, r-CΔ170, r-CΔ10–15 and r-CR84G in
AGMs might be due to differences in their sensitivity to type I
IFN. Vero cells, an AGM cell line that is sensitive to the antiviral
effects of exogenous human IFN, were selected for use in these
experiments because they lack the structural genes for IFN-α
and IFN-β (Emeny and Morgan, 1979; Wathelet et al., 1992), a
property that permits an evaluation of responses to human IFN in
the absence of endogenous IFN production. Replicate cultures of
Vero cells were either untreated or treated with IFN-α or IFN-β
at 1, 10, 100 and 1000 international units per ml (IU/ml) and 0.1,
1, 10, 100, 1000 and 5000 IU/ml, respectively, for 24 h prior to
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63W. Van Cleve et al. / Virology 352 (2006) 61–73infection with the indicated rHPIV1s at a multiplicity of in-
fection (MOI) = 5.0 TCID50/cell (Fig. 1). The reduction in virus
present in the supernatant of IFN-treated cells compared to
untreated cells after 24 h of infection was measured to assess the
level of sensitivity of the rHPIV1s to the antiviral effect of type I
IFN. Mutants and r-wt virus demonstrated equivalent levels of
sensitivity to IFN-α and -β pre-treatment (Fig. 1). Interestingly,
the mean maximum reduction in virus titer in response to IFN-α
was 2.0 log10 50% tissue culture infectious dose per milliliter
(log10 TCID50/ml) at 1000 IU/ml, and for IFN-β the reduction in
virus titer reached a plateau with 100, 1000 and 5000 IU/ml at
2.8 log10 TCID50/ml (Fig. 1), indicating that rHPIV1s are appro-
ximately 10-fold more sensitive to IFN-β than IFN-α. Clearly,
the difference in attenuation of the HPIV1 wt and mutant virus in
AGMs was not related to a difference in the sensitivity of the
viruses to the antiviral activity of IFN (Table 1). However, the
findings did indicate that the r-wt is sensitive to IFN and,
therefore, likely has evolved, like SeV, a strategy to disable the
host's IFN response.
Type I IFN production in response to wild-type and mutant
rHPIV1 infection
The level of type I IFN production in response to infection
with the panel of rHPIV1s was measured in A549 cells, a human
respiratory epithelial cell line with a competent IFN system
(Spann et al., 2004). A549 cell monolayers were infected with
the indicated rHPIV1s (MOI = 5.0 TCID50/cell) or a vesicular
stomatitis virus (VSV) control (MOI = 5.0 PFU/cell) (Fig. 2).
Supernatants were removed at 12, 24, 48, 72 and 96 h post-
infection and an IFN bioassay was performed against an IFN-β
standard. There was no detectable type I IFN in the supernatants
of A549 cells infected with r-wt, r-CΔ10–15 or, somewhat
surprisingly, the VSV control at the time points indicated in Fig.
2. However, type I IFN was detected in the supernatant of VSV-
infected cells at 8 and 10 h post-infection (78 and 312 pg/ml,
respectively) by IFN bioassay on A549 cells (data not shown),
although IFN could not be detected in any rHPIV1-infected cells
at these early time points. In contrast, type I IFN was detected in
the supernatants of r-CR84G, r-CΔ170 and r-CF170S infected cells,
with peak levels occurring between 48 and 96 h post-infection
(Fig. 2). The lack of IFN induction by r-wt and r-CΔ10–15, taken
together with the strong IFN response to r-CR84G, r-CΔ170 and
r-CF170S, suggested that r-wt and r-CΔ10–15 possess a mecha-
nism that inhibits the induction of IFN whereas this mechanism
is impaired for r-CR84G, r-CΔ170 and r-CF170S. Because the
F170S mutation in C affects only the C protein but not P, these
findings indicate that the C protein of HPIV1 mediates the
inhibition of IFN production by A549 cells.
Detection of type I IFN mRNA expression in response to
infection with wild-type and mutant rHPIV1s
We next sought to examine if the different quantities of IFN
produced during infection of A549 cell cultures with r-wt or the
mutant viruses was reflected in the level of mRNA for IFN-α and
IFN-β present in the infected cells. In addition, a limitation of the
Fig. 1. Sensitivity of wild-type and mutant rHPIV1s to (A) IFN-α and (B) IFN-β. Vero cells were treated with IFN-α and IFN-β at 1, 10, 100 and 1000 IU/ml and 0.1,
1, 10, 100, 1000 and 5000 IU/ml, respectively, for 24 h prior to infection with rHPIV1s at MOI = 5.0 TCID50/cell. Virus titers were determined in the supernatant at
24 h post-infection. The data are presented as reduction in virus titer (log10 TCID50/ml) in IFN-treated versus untreated cells. See Materials and methods section for
explanation of use of error bars for the SE.
64 W. Van Cleve et al. / Virology 352 (2006) 61–73type I IFN bioassay is that it does not distinguish between IFN-α
and IFN-β, whereas these can be distinguished at the mRNA
level. A549 cell monolayers were infected with an rHPIV1
(MOI = 5.0 TCID50/cell) or VSV (MOI = 5.0 PFU/cell), and total
RNAwas extracted at 8, 12, 24, 48, 72 and 96 h post-infection
(Fig. 3). mRNAs specific for human IFN-β and two groups of
IFN-α subtypes were quantified by qRT-PCR using previously
described specific primers and Taqman probes (Spann et al.,
2004). The results for the IFN-β probe and for IFN-α probe set 1,
which was specific for IFN-α1, IFN-α6 and IFN-α13, are shownFig. 2. Comparison of the IFN response in A549 cells to infection with wild-type and
TCID50/cell) or VSV (MOI = 5.0 PFU/cell) and the amount of type 1 IFN in the cel
infection in parallel with an AVONEX® IFN-β standard. IFN concentration is expr
approximately 1 IU of antiviral activity per 5 pg. This figure is representative of 5 iin Fig. 3; the results for IFN-α primer set 2 were identical to
those of set 1 (data not shown). For each sample, the amount of
each IFN mRNA or mRNA set was calculated relative to that of
β-actin and expressed as a fold increase compared to the mock-
infected sample.
There was no detectable IFN-α mRNA in cells infected with
any of the rHPIV1s (Fig. 3), although this set of mRNAs was
induced by VSV confirming the functionality of the detection
system. VSV induction of IFN mRNA at these later time points
may be indicative of induction of a second late IFN response.mutant rHPIV1s. A549 cell monolayers were infected with rHPIV1s (MOI = 5.0
l supernatants was determined by IFN bioassay at 12, 24, 48, 72 and 96 h post-
essed in pg/ml ± SE. The AVONEX® IFN-β standard has a specific activity of
ndependent experiments, with every time point performed at least three times.
Fig. 4. Identification of dimerized IRF-3 in HPIV1-infected A549 cells. Lysates
were prepared from A549 cells, which were mock-infected or infected with virus
including HPIV1 wt, r-CΔ10–15, r-CR84G, r-CΔ170, r-CF170S or VSV, at 24 h post-
infection. The Bradford assay was used to measure total cell proteins for even
loading. Cell lysates were resolved by PAGE electrophoresis under native
conditions. Western blot was used to identify both monomeric and dimeric forms
of IRF-3.
Fig. 3. Level of human IFN-α and IFN-β mRNA expression in A549 cells
infected with wild-type andmutant rHPIV1s or VSV. A549 cell monolayers were
infected with the indicated wild-type or mutant rHPIV1 (MOI = 5.0 TCID50/cell)
or VSV (MOI = 5.0 PFU/cell), and total RNAwas extracted at 8, 12, 24, 48, 72
and 96 h post-infection. (A) IFN-α and (B) IFN-βmRNAweremeasured by qRT-
PCR using specific primers and Taqman probes that have been previously des-
cribed (Spann et al., 2004). The IFN-α primer/probes were specific to IFN-α1, -6
and -13. For each sample, the level of each IFN mRNAwas relative to that of β-
actin and expressed as a fold increase compared to that for the mock-infected
sample.
65W. Van Cleve et al. / Virology 352 (2006) 61–73Because IFN activity was detectable at early time points fol-
lowingVSVinfection ofA549 cells by bioassay (8 and 10 h post-
infection, data not shown), but at later time points no IFN activity
is detectable, this suggests that the production of IFN was in-
hibited by VSV-mediated shut-off of cellular protein synthesis.
There also was no IFN-β mRNA detectable at any time point in
response to r-wt (Fig. 3), but IFN-βmRNAwas detected as early
as 8 h in the VSV control and by 24 h in response to most of the
various mutant rHPIV1s (Fig. 3). The IFN mRNAs were de-
tected earlier than was IFN in media supernatants by bioassay
(compare Fig. 2 with Fig. 3) indicating the greater sensitivity of
the mRNA detection assay. The r-CF170S virus induced the
strongest IFN-βmRNA response, peaking at 48 h post-infection
(Fig. 3). The r-CΔ170 and r-CR84G viruses also induced a strongIFN-β mRNA response (Fig. 3). There was a very low level of
IFN-βmRNA detected in response to the r-CΔ10–15 virus at 72 h
post-infection. The results of the qRT-PCR correlated well with
the results of the type I IFN bioassay, in that (i) r-wt inhibited the
production of IFN-βmRNA and type I IFN activity; (ii) r-CΔ10–
15 was associated with low to undetectable levels of IFN-β
mRNA and type I IFN activity; and (iii) r-CF170S, r-CΔ170 and r-
CR84G induced substantial levels of IFN-βmRNAand type I IFN
activity. These results imply that IFN production is abrogated in
response to r-wt and r-CΔ10–15 infection by inhibition of syn-
thesis of IFN, whereas IFN synthesis occurs during infection
with r-CF170S, r-CΔ170 or r-CR84G. Therefore, induction of IFN
production during infection with rHPIV1s is directly correlated
with attenuation in AGMs, with the exception of r-CR84G (Table
1), which induced IFN mRNA and protein but was not signi-
ficantly restricted in replication in AGMs (Bartlett et al., 2005).
IRF-3 activation in cells infected with rHPIV1s
Viral infection of a cell initiates a cascade leading to the
sequential phosphorylation, dimerization and nuclear transloca-
tion of the transcription factor IRF-3 that binds to and activates
the promoters of the genes of the early IFNs, IFN-α1 and IFN-β
in human cells (Yoneyama et al., 1998). Therefore, the local-
ization and dimerization of IRF-3 in A549 cells infected with
rHPIV1s was monitored in order to evaluate at which stage
HPIV1 interferes with IFN production. A549 cells were infected
with rHPIV1s at MOI = 2.0 TCID50/cell; at 24 h post-infection,
dimerization assays were performed; and at 48 h post-infection,
the IRF-3 (FITC-green) and HPIV1 HN (Texas red) proteins
were detected in situ by immunofluorescence. This demonstrat-
ed that the r-wt and r-CΔ10–15 viruses, which inhibited the
production of IFN-β mRNA and type I IFN protein, also inhi-
bited IRF-3 dimerization (Fig. 4) and nuclear localization of
IRF-3 (Figs. 5A and B). In contrast, the r-CF170S, r-CΔ170 and
r-CR84G, which were associated with induction of IFN-βmRNA
expression and type I IFN protein, also induced IRF-3 dime-
rization (Fig. 4) and nuclear localization (Figs. 5A and B). There
was no IRF-3 dimer observed in mock-infected cells; however,
VSV-infected cells, in which activation of the IFN response is
induced, demonstrated an IRF-3 dimer. IRF-3 nuclear localiza-
tion was quantified for each virus by determining the percentage
Fig. 5. IRF-3 localization in A549 cells following infection with wild-type or mutant rHPIV1s. (A) A549 cell monolayers were infected with rHPIV1s at MOI = 2.0
TCID50/cell and, 48 h post-infection, were fixed, permeabilized and analyzed by immunofluorescence with antibodies for the HPIV1 HN protein (Texas red) and
human IRF-3 (FITC-green) to determine IRF-3 localization in virus-infected cells. (B) The percentage of infected cells demonstrating nuclear translocation of IRF-3
was determined for each virus (n = ≥70, combined total). The data presented are representative of two similar experiments.
66 W. Van Cleve et al. / Virology 352 (2006) 61–73of virus-infected cells positive for nuclear IRF-3 (Fig. 5B). For r-
wt and r-CΔ10–15, only 6% and 23%, respectively, of infected
cells demonstrated IRF-3 nuclear translocation (Fig. 5B). For the
mutants unable to inhibit IFN induction, r-CF170S, r-CΔ170 and r-
CR84G, 74%, 81.5% and 71%, respectively, of infected cells were
positive for IRF-3 in the nucleus. These results indicate that r-wt
and r-CΔ10–15 inhibit IRF-3 dimerization and nuclear accumu-
lation of IRF-3 and that this correlates well with the lack of
detectable IFN response during infection with these viruses.
Therefore, it appears that HPIV1 C wt proteins inhibit the
production of IFN at a step preceding IRF-3 dimerization and
nuclear translocation, inhibitory activities that are disabled in r-
CF170S, r-CΔ170 and r-CR84G. The nuclear localization of IRF-3
during rHPIV1 infection correlates with attenuation in AGMs,
again with the exception of r-CR84G (Table 1). The IRF-3
localization study was performed in various other human (HEp-
2) and non-human primate cells (LLC-MK2 andVero); however,
it appears to be a cell-type-specific phenomenon, which is not
unexpected because A549 cells are alveolar epithelial cells and
therefore HPIV1 growth in these cells reflects the in vivo
pathology of the virus.Inhibition of IFN signaling following rHPIV1 wt and mutant
infection of Vero cells
To determine whether rHPIV1 infection affects IFN signaling
leading to the establishment of an antiviral state, we mock-
infected or infected Vero cells in 6-well plates with r-wt, r-
CF170S, r-CΔ170, r-CΔ10–15 or r-CR84G at MOI = 5.0 TCID50/cell,
incubated for 48 h, treated with 0, 1, 10, 100 or 1000 IU/ml of
IFN-β for 24 h and infected with 100 plaque forming units
(PFU) per well VSVexpressing green fluorescent protein (GFP).
The number of VSV-GFP foci per well was determined 48 h
later. The control group that was not infected with an rHPIV1
showed that VSV-GFP replication was sensitive to IFN-β at 100
and 1000 IU/ml (Fig. 6). Infection with r-wt and r-CΔ10–15
inhibited the ability of IFN-β, at any of the tested concentrations,
to restrict replication of VSV-GFP (Fig. 6). Conversely, infection
with r-CF170S and r-CΔ170 did not inhibit the ability of IFN to
restrict the replication of VSV and thus resembled the mock-
infected control group. These findings indicate that the intro-
duction of the CF170S or CΔ170 mutation into HPIV1 abrogates
the inhibition of IFN signaling seen in wt HPIV1-infected cells.
Fig. 6. Effect of infection with wild-type or mutant rHPIV1on IFN signaling in Vero cells. Vero cells in 6-well plates were infected with the indicated rHPIV1s at
MOI = 5.0 TCID50/cell for 48 h. Cells were then left untreated (2 wells per virus) or treated with 1, 10, 100 or 1000 IU/ml IFN-β (1 well per treatment per virus) for
24 h. The cells were then infected with VSV-GFP and incubated for 48 h. The VSV-GFP foci were visualized using a phosphorimager. The data presented are
representative of two similar experiments.
67W. Van Cleve et al. / Virology 352 (2006) 61–73Infection with the r-CR84G virus caused a moderate reduction in
the number of VSV-GFP plaques at 1000 IU/ml; however, this
effect was not as dramatic as that seen for r-CF170S and r-CΔ170
(Fig. 6). Interestingly, the VSV-GFP plaque sizes observed in the
r-CR84G-infected plates were reduced by 45% and 60% in the
100 and 1000 IU/ml IFN-β treatment groups, respectively (data
not shown). The inability to inhibit IFN signaling by the r-CF170S
and r-CΔ170 viruses also correlates with attenuation in AGMs
(Table 1). Because the F170S mutation in C affects only the C
proteins but not the P protein, these findings implicate the
HPIV1 C proteins as inhibitors of IFN signaling, as has been
previously demonstrated for SeV (Didcock et al., 1999a; Garcin
et al., 2000, 2004; Gotoh et al., 2003).
Discussion
HPIV1 wt and recombinant P/C gene mutants, r-CF170S, r-
CΔ170, r-CΔ10–15 and r-CR84G, were evaluated in human lung
epithelial cells (A549) or in closely related monkey cells (Vero)for their sensitivity to IFN, for their ability to induce the pro-
duction of IFN and for their ability to modify the antiviral state
induced in infected cells by exogenous IFN. These mutants had
previously been evaluated for attenuation in hamsters and
AGMs (Bartlett et al., 2005, 2006; McAuliffe et al., 2004;
Newman et al., 2004). The r-wt and r-CR84G viruses replicated
efficiently in both species; r-CF170S and r-CΔ170 were restricted
in replication in both species; and r-CΔ10–15 was attenuated for
hamsters only. Thus, the P/C mutants exhibited a spectrum in
their level of attenuation for AGMs, and the present study
investigated whether this spectrum of attenuation could be cor-
related with effects on the host IFN response. The CR84G, CF170S
and r-CΔ170 mutations are among the attenuating mutations that
have been developed for inclusion in live attenuated rHPIV1
vaccine candidates, and an understanding of the basis for their
attenuation is important.
Most viruses are susceptible to the antiviral state induced by
IFN, and for this reason many viruses have evolved strategies to
evade the IFN response (Conzelmann, 2005; Goodbourn et al.,
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HPIV1 to human IFN was not known, and in the present study it
was found that HPIV1 wt and the P/C mutants were indeed
sensitive to the antiviral state induced by IFN-α or IFN-β
indicating that that HPIV1 cannot readily overcome an
established antiviral state, at least in this experimental setting.
In humans, IFN-β and IFN-α1 are induced as the first step in
the IFN response (Lin et al., 2000; Yeow et al., 2001). IFN-β is
one of the best studied of the type I IFN subtypes (Goodbourn et
al., 2000; Grandvaux et al., 2002; Leineweber et al., 2004; Levy
and Garcia-Sastre, 2001; Taniguchi and Takaoka, 2002), and
recognition of intermediates in viral replication leads to IFN-β
production. Specifically, intracellular viral dsRNA is recognized
by host cell proteins such as the retinoic acid inducible gene-1
(RIG-1) cytoplasmic protein (Yoneyama et al., 2004), which
subsequently associates with a newly identified protein, mito-
chondrial antiviral signaling (MAVS) protein (Seth et al., 2005;
Xu et al., 2005). Extracellular viral dsRNA is recognized by
Toll-like receptor (TLR)-3 (Beutler, 2004), which results in the
activation of TRIF-mediated pathways (Fitzgerald et al., 2003;
Sharma et al., 2003). Both events lead to the activation of kinases
(IKK-ε and TBK-1), which in turn phosphorylate IRF-3, re-
sulting in IRF-3 dimerization and nuclear translocation. IRF-3
along with nuclear factor-κB (NF-κB) and ATF-2/c-Jun bind to
the IFN-β gene promoter to activate IFN-β transcription (Yie et
al., 1999).
In the present study, we demonstrated that the C proteins of
HPIV1 inhibit IRF-3 activation and subsequent IFN production.
In A549 cells, infection with HPIV1 resulted in minimal nuclear
localization of IRF-3, did not induce detectable IRF-3
dimerization, did not increase IFN-α and IFN-β mRNA
expression, and did not induce the production of biologically
active type I IFN. A mutant bearing a deletion of codons 10–15
(r-CΔ10–15) inhibited IFN production in human cells, like HPIV1
wt. In contrast, a point mutation in or deletion of codon 170 in C
(r-CF170S and r-CΔ170) disabled the ability of the virus to inhibit
IFN production, as evidenced by the detection of IRF-3 dimers
and a significant level of IRF-3 nuclear translocation, indicative
of IRF-3 activation, induction of IFN-β mRNA synthesis and
secretion of biologically active type I IFN. Because r-CF170S
contains only a mutation in C without an accompanying coding
mutation in P, it is clear that the C protein of HPIV1 is
responsible for the ability of HPIV1 wt to inhibit the IFN
response. Similarly, the mutation at codon 84 (r-CR84G) allowed
the formation of IRF-3 dimers, disabled the ability of the virus to
inhibit IRF-3 nuclear localization and conferred a moderate
increase in both IFN-βmRNA and biologically active type I IFN
synthesis.
Many viruses have been demonstrated to express viral pro-
teins that inhibit IFN production, and these proteins usually
interfere with IRF-3 activation or function. For example, para-
myxovirus V proteins have been shown to bind to the RNA
helicase mda-5, a close relative of RIG-I, which inhibits dsRNA
recognition of mda-5 and thus prevents downstream IRF-3 acti-
vation (Andrejeva et al., 2004). The RSV NS1 and NS2 proteins
(Bossert et al., 2003; Spann et al., 2004, 2005) and SeV C and V
proteins (Komatsu et al., 2004) also have been shown to inhibitIRF-3 activation. Alternatively, the NSP1 protein of rotavirus
induces IRF-3 degradation (Barro and Patton, 2005); the HSV-1
ICP0 protein blocks nuclear localization of IRF-3 by a phos-
phorylation-independent mechanism (Melroe et al., 2004); and
Thogotovirus, an orthomyxovirus, although permissive for IRF-
3 nuclear localization, blocks IRF-3 dimerization and CBP re-
cruitment (Jennings et al., 2005). Here we have demonstrated
that the HPIV1 C protein antagonizes type I IFN production by
inhibiting IRF-3 activation; however, the mechanism of how the
C protein of HPIV1 achieves this remains to be elucidated.
In humans, a single IFN-β protein and 14 distinct IFN-α
proteins are produced, and they signal through a common
receptor (Bekisz et al., 2004). Evidence that the multiple
human IFN-α proteins possess distinct immunomodulatory
(Hibbert and Foster, 1999; Hilkens et al., 2003; Yanai et al.,
2002), antiproliferative (Hu et al., 1993) and antiviral
properties (Foster et al., 1996; Havell et al., 1978) is
accumulating (Foster and Finter, 1998). As noted above,
IFN-α1 is considered a member of the early human IFNs,
along with IFN-β, because activated IRF-3 has been
demonstrated to bind and activate its promoter, a property
that distinguishes it from the other 13 IFN-α subtypes (Lin et
al., 2000; Yeow et al., 2001). Therefore, we were surprised to
find that IFN-α mRNA was not detected in response to
infection with any of the rHPIV1s, in particular the HPIV1 P/C
mutants, r-CF170S, r-CΔ170 and r-CR84G, which demonstrated
nuclear localization of IRF-3 during infection. However, IFN-
β was produced following infection with these viruses, and we
would expect that an HPIV1 mutant permissive for IFN-β
production would be similarly permissive for IFN-α1 produc-
tion. We were also surprised that no other IFN-α mRNA
species were produced during infection with any of the wild-
type or mutant HPIVs, although the VSV control confirmed
that these cells can respond to viral infection by producing
IFN-α mRNA. Because some synthesis of IFN-α mRNA also
was obtained in this same system in response to wild-type and
mutant RSV (Bossert et al., 2003; Spann et al., 2004, 2005),
the lack of detectable IFN-α mRNA in the present study is
suggestive of effects specific to HPIV1. Induction of most of
the species of IFN-α depends on IRF-7 (Marie et al., 1998),
which is IFN inducible and is activated in a fashion similar to
that of IRF-3. It is possible that the HPIV1 C proteins also
block the IFN response by inhibiting activation or functioning
of IRF-7. The mechanism responsible for the restricted
synthesis of IFN-α mRNA and protein during HPIV1 infection
and the role played other IRFs in this restriction require
additional study.
Following its secretion from a cell, type I IFN binds to the
IFN-α/β receptor and triggers signaling through the Janus
kinase/signal transducer and activator of transcription (JAK/
STAT) pathway (Goodbourn et al., 2000; Grandvaux et al.,
2002; Levy and Garcia-Sastre, 2001; Samuel, 2001; Taniguchi
and Takaoka, 2002; Weber et al., 2004). This pathway controls
transcription of the IFN-stimulated genes, which comprise more
than 300 genes that have a broad range of antiviral, anti-
proliferative and immunomodulatory functions, and include
proteins such as ds-RNA-activated protein kinase (PKR), 2′-5′-
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and Garcia-Sastre, 2001).
Paramyxovirus C and V proteins have been shown to block
the IFN signaling cascade by various mechanisms, including
STAT binding (Garcin et al., 2002; Takeuchi et al., 2001),
induction of STAT destabilization (Garcin et al., 2000; Parisien
et al., 2001), proteasomal degradation of STAT proteins
(Didcock et al., 1999b; Ulane et al., 2005), inhibition of STAT
activation (Gotoh et al., 2003) and impaired phosphorylation/
dephosphorylation of STAT1 (Komatsu et al., 2002; Malur et al.,
2005). The data presented here for HPIV1 demonstrate a role for
the C proteins in inhibiting IFN signaling because infection with
HPIV1 inhibited the IFN-induced antiviral state in Vero cells,
and this effect was abrogated by a mutation in C. Specifically, an
intact response to exogenous IFN was mounted following in-
fection with the C mutant, r-CF170S, indicating that this mutation
abrogates the ability of the C proteins to inhibit IFN signaling.
This is strong evidence indicating that the HPIV1 wt C proteins
interfere with both IFN production and IFN signaling through its
receptor. However, the mechanism for inhibition of IFN signal-
ing by the C proteins has yet to be elucidated.
The importance of the C proteins in virus replication is
highlighted by several studies demonstrating in vivo attenuation
of recombinant paramyxoviruses with deleted C proteins,
including SeV, HPIV3 and measles virus (Durbin et al., 1999;
Kurotani et al., 1998; Takeuchi et al., 2005). The present study
extends these previous findings by demonstrating that muta-
tions in the C proteins of HPIV1 that disable the inhibition of
both IFN production and signaling in human and monkey cells
also confer attenuation in AGMs. The r-wt and r-CΔ10–15
viruses that replicate efficiently in AGMs (Bartlett et al., 2005,
2006) maintain their IFN antagonist functions and inhibit both
IFN production and signaling. In contrast, r-CF170S and r-CΔ170,
which were attenuated in AGMs (Bartlett et al., 2005, 2006),
have lost their IFN antagonist functions, that is, IFN was
produced and an IFN-induced antiviral state was established
following treatment of infected cells with exogenous IFN.
However, r-CR84G, a mutant that was not attenuated in AGMs,
also lost its ability to inhibit IFN production in infected cells but
maintained its ability to antagonize IFN signaling through its
receptor. This set of observations suggests that loss of both
antagonist functions, or at least loss of inhibition of signaling, is
required to restrict replication in AGMs. The importance of the
observation that attenuation of some of the paramyxoviruses is
best achieved by loss of both IFN antagonist functions is
supported by the observations that many of the paramyx-
oviruses have accessory proteins that inhibit both arms of the
IFN response including SeV C proteins (Garcin et al., 2000,
2004; Gotoh et al., 2003; Komatsu et al., 2004), RSV NS1/2
proteins (Bossert et al., 2003; Lo et al., 2005; Ramaswamy et
al., 2005; Spann et al., 2005) and SV5 V proteins (Didcock et
al., 1999b; He et al., 2002; Poole et al., 2002), as do other
viruses of the Mononegavirales family such as the P protein of
rabies virus (Brzozka et al., 2005; Vidy et al., 2005). Mutations
in the IFN antagonist proteins that inhibit both antagonist
functions are likely to be more attenuating than mutations that
affect only one arm of the IFN response.The specific regions of the HPIV1 C proteins involved in IFN
inhibition have yet to be mapped. However, evaluation of pre-
vious in vivo studies combined with the in vitro studies
presented here enables us to draw some conclusions. The
r-CΔ10–15, like r-wt, inhibited the IFN response and replicated
efficiently in AGMs (Bartlett et al., 2006). This indicates that the
N-terminal region around amino acids 10–15 of C is not essen-
tial for the inhibition of the IFN response in monkey and human
cells. However, SeV and HPIV1 recombinants bearing this
mutation were attenuated in rodents, and, in SeV, the CΔ10–15
mutation exhibited modified IFN antagonism. The N-terminal
end of the C proteins is unique to C′ and C and has been impli-
cated in the ubiquitination and degradation of STAT1 (Garcin et
al., 2001). The latter study was performed in mouse embryo
fibroblasts, and it was further shown that deleting codons 10–15
inhibited the ability to degrade STAT. Clearly, the CΔ10–15
mutation is active in a species-specific manner, that is, active in
rodents but not in AGMs (Bartlett et al., 2006). In contrast, the
region containing codons 84 and 170 is essential to inhibiting the
production of IFN in human and monkey cells because mutation
in this region disables this inhibition, as observed following
infection with r-CF170S, r-CΔ170 and r-CR84G. Interestingly,
although the r-CR84G mutant had lost the ability to inhibit IFN
production, it retained the ability to inhibit IFN signaling, indi-
cating that the region containing codon 84 differentially affects
IFN production and signaling. This region also specifies an
additional host-specific response because this mutation is atte-
nuating in AGMs but not hamsters. Thus, we have correlated
effects on the IFN system in cultured cells with attenuation in a
non-human primate and have mapped regions in C involved in
host-specific effects.
Materials and methods
Cells and viruses
LLC-MK2 cells (ATCC CCL 7.1) and HEp-2 cells (ATCC
CCL 23) were maintained in Opti-MEM I (Gibco-Invitrogen,
Inc. Grand Island, NY) supplemented with 5% FBS (Hyclone,
Logan, UT) and 50 μg/ml gentamicin sulfate (Gibco-Invitrogen,
Inc.). Vero cells (ATCC CCL-81) were maintained in Opti-PRO
SFM (Gibco-Invitrogen, Inc.) supplemented with 50 μg/ml
gentamicin sulfate and 4 mM L-glutamine. A549 cells (ATCC
CCL-185) were maintained in F-12 nutrient mixture (HAM)
(Gibco-Invitrogen Inc.) supplemented with 10% FBS, 50 μg/ml
gentamicin sulfate and 2 mM L-glutamine.
The r-wt and mutants, r-CΔ10–15, r-CR84G, r-CF170S and
r-CΔ170, were recovered previously using support plasmids
containing the appropriate mutations (Bartlett et al., 2006;
Newman et al., 2002). All media used for rHPIV1 propagation
and infection contained 5 μg/ml trypsin (BioWhittaker, Walk-
erville, MD) without FBS. Stocks of rHPIV1s were grown in
Vero cells and purified by centrifugation and banding in dis-
continuous 30–60% (w/v) sucrose gradients, steps designed to
minimize contamination by cellular factors, especially IFN.
Virus titers were determined by 10-fold serial dilution of virus in
96-well LLC-MK2 monolayer cultures, using four wells per
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hemadsorption with guinea pig erythrocytes as described pre-
viously (Hall et al., 1992; Skiadopoulos et al., 2002). Virus titers
are expressed as log10 TCID50/ml. The identity of each rHPIV1
was confirmed by sequence analysis of the relevant genes to
confirm the presence or absence of mutations.
Recombinant VSV-GFP was obtained from John Hiscott
(Stojdl et al., 2003). Stocks of VSV-GFP were propagated and
titered in Vero cells. Titers are expressed as PFU/ml.
Virus infections
HPIV1 viral assays were performed at 32 °C on Vero and
A549 cells. Cells were infected at an MOI of 5.0 TCID50/cell for
all viral assays, except where otherwise stated. VSV-GFP
infections were performed in Vero cells at MOI = 5.0 PFU/cell.
Plaque assays were performed using VSV-GFP and the
infection was overlaid with 0.8%methylcellulose in the relevant
cell culture media.
Sensitivity of HPIV1s to IFN
The r-wt, r-CΔ10–15, r-CR84G, r-CF170S and r-CΔ170 viruses
were evaluated for their sensitivity to an established IFN-in-
duced antiviral state. Vero cells were pre-treated with IFN-α-2b
(INTRONA, Schering Corporation, Kenilworth, NJ) and IFN-β
(AVONEX, Biogen, Cambridge,MA) at 1, 10, 100 and 1000 IU/
ml and 0.1, 1, 10, 100, 1000, 5000 IU/ml, respectively, for 24 h.
Cells were infected with rHPIV1s at MOI = 5.0 TCID50/cell and
either treated with IFN (3 replicates per IFN concentration) or
left untreated (6 replicates). Supernatants were taken at 0 and
24 h post-infection and virus titers determined by titration on
LLC-MK2 cells. Themean virus titer in untreated, virus-infected
cells at 24 h was compared with that in IFN-treated, infected
cells at each IFN concentration to derive a mean reduction in
virus titer. Some values represent data compiled from multiple
experiments: that is, a mean of several independent mean titer
reductions, and these values are presented as the reduction in
virus titer (log10 TCID50/ml) ± standard error (SE) bars in Fig. 1.
For values from a single experiment (a single mean from 3
replicate cultures), the titer reduction is presented without SE
bars (Fig. 1).
IFN bioassay
The amount of IFN produced by infected A549 cells was
determined by IFN bioassay following published methods (Park
et al., 2003). Briefly, cell supernatants were treated at pH 2.0 for
24 h at 4 °C to inactivate virus and acid-labile type II IFN, and
samples were then adjusted to pH 7.0 by addition of 2 M NaOH.
Type I IFN titers in samples were determined by measuring
restriction of replication of VSV-GFP on HEp-2 cell monolayer
cultures in comparison to a known concentration of a human
IFN-β standard (AVONEX). IFN-β standard (5000 pg/ml) and
IFN-containing samples were serially diluted 10-fold in
duplicate in 96-well plates of HEp-2 cells. After 24 h, the cells
were washed and infected with VSV-GFP at 105 PFU/well.Control cultures (no VSV-GFP, no IFN and VSV-GFP, no IFN)
were performed in quadruplicate on each plate. After an addi-
tional 24 h, plates were read for total GFP expression on a
Typhoon phosphorimager using a Typhoon 8600 scanner (Mole-
cular Dynamics Inc., Sunnyvale, CA) control program (settings:
fluorescence; filter, 526-SP green fluorescein). The dilution at
which the level of GFP expression was approximately 50% of
that in untreated cultures was determined to be the end-point.
The end-point of the AVONEX standard was compared to the
end-point of the unknown samples, and IFN titers were deter-
mined. Titers are expressed as mean ± SE (pg/ml) sera. Accord-
ing to the manufacturers, using the World Health Organization
natural IFN-β standard, the AVONEX IFN-β has a specific
activity of approximately 1 IU of antiviral activity per 5 pg.
IFN mRNA qRT-PCR
The levels of IFN-α and IFN-β mRNA in cell cultures
infected with r-wt and rHPIV1 mutants relative to mock-
infected cultures were determined by qRT-PCR as previously
described (Spann et al., 2004). Briefly, total RNA was
extracted from cell cultures using the RNeasy total RNA
isolation kit (QIAGEN, Valencia, CA). RNA was reverse
transcribed using an oligo(dT) primer and reagents from the
Brilliant 2-step qRT-PCR kit (Stratagene, La Jolla, CA). The
PCR primers and Taqman probes used to detect human IFN-β,
two specific sets of human IFN-α, and β-actin have been
described previously (Spann et al., 2004). IFN-α primer set 1
was specific for human IFN-α1, -6 and -13 and IFN-α set 2
was specific for human IFN-α4, -5, -8, -10, -14, -17 and -21.
Duplex q-PCR reactions were performed to allow comparison
between IFN and the housekeeping gene, β-actin. The probe
for β-actin was labeled with the reporter dye 5-carboxyfluor-
escein (FAM) at the 5′ end, and all IFN probes were labeled
with the reporter dye 5′ HEX at the 5′ end and BHQ1 at the 3′
end. Reactions contained a passive reference dye, which was
not involved in amplification of IFN or β-actin, but was used to
normalize the probe reporter signals. Positive control curves
were performed using preparations known to contain high
levels of IFN cDNA to ensure reaction efficiency. Each
reaction signal was corrected individually for β-actin signal; in
addition, signals from all reactions from virus infected samples
were corrected against the signal generated in a mock-infected
well, resulting in a β-actin-corrected measurement of fold-
expression over mock.
Determination of IRF-3 localization during rHPIV1 infection
A549 cells in slide chambers were mock-infected or infected
with r-wt and mutants at MOI = 2.0 TCID50/cell. IRF-3 and
HPIV1 HN antigens were detected in the cells by immunoflu-
orescence, as described below, at 48 h post-infection, because
this was the time point at which peak IFN production was de-
monstrated following HPIV1 infection. The percentage of in-
fected cells demonstrating nuclear localization of IRF-3 was
determined for each virus in two independent experiments
(n ≥ 70).
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A549 cells were grown in slide chambers (Nunc, Rochester,
NY) and treated with virus, as described. Cells were washed
with PBS containing Ca+ and Mg+ (PBS++), fixed with 3%
formaldehyde, permeabilized with 0.1% Triton X-100/PBS++,
blocked in PBSA (PBS++/0.25% BSA/0.25% gelatin) for 1 h
and then incubated with the primary antibody for 1 h at 37 °C.
Primary antibodies included (i) rabbit anti-IRF-3 (Santa Cruz
Biotechnology, Inc, Santa Cruz, CA; catalogue # sc-9082),
diluted 1:50 in PBSA; and (ii) mouse anti-HPIV1 HN (8.2.2A),
kindly provided by Yasuhiko Ito, Mie University School of
Medicine, diluted 1:2000 in PBSA. The slide chambers were
washed with PBSA and the secondary antibody was applied for
1 h at a dilution of 1:500 in PBSA. Secondary antibodies
included (i) Fluorescein (FITC)-conjugated affinipure donkey
anti-rabbit IgG (Jackson ImmunoResearch Laboratories, Inc,
West Grove, PA; catalogue # 711-095-152); and (ii) Texas red
dye-conjugated affinipure donkey anti-mouse IgG (Jackson
ImmunoResearch Laboratories, Inc, West Grove, PA; catalogue
# 715-075-151), respectively. Slide chambers were washed 3
times and treated with 4′6-diamidino-2-phenyindole-dilactate
(Sigma, St. Louis, MO, USA), diluted 1:2500 in PBS++, for
15 min. After a final wash, cells were overlaid with Vectashield
(Vector laboratories, Inc, Burlingame, CA). Slides were
examined using confocal microscopy.
Effect of HPIV1 on signaling of IFN through its receptor
Vero cells in 6-well plates were infected with r-wt and
mutants at MOI = 5.0 TCID50/cell for 48 h. Cells were then left
untreated (2 wells per virus) or treated with 1, 10, 100 or
1000 IU/ml IFN-β (1 well per treatment per virus) for 24 h prior
to infection with VSV-GFP. Infected cells were cultured under a
0.8% methylcellulose overlay prepared in Opti-PRO SFM
(Gibco-Invitrogen, Inc.) supplemented with 50 μg/ml gentami-
cin sulfate and 4 mM L-glutamine. Plates were read for GFP
expression 48 h after VSV-GFP infection using a phosphor-
imager, and the number of VSV-GFP-positive foci was counted.
The data presented are representative of two experiments.
Native-PAGE for identification of IRF-3 dimers in
HPIV1-infected cells
IRF3 monomers and dimers were detected using Western
blot. A549 cells in 6-well plates were mock-infected or infected
with HPIV1 wt and mutants at MOI = 5.0 TCID50/cell for 24 h.
The cells were lysed in buffer containing 50 mM Tris–HCl (pH
8.0), 150 mM NaCl, 1% Nonidet P-40, 5 mM sodium ortho-
vanadate, 100 mg/ml leupeptin and 1 mM phenylmethylsulpho-
nylfluoride (PMSF). The Bradford assay (Better Bradford assay
kit, Pierce, Rockford, IL, USA) was used, according to manu-
facturer's instructions, to measure total cell proteins for even
loading. Native-PAGE was performed using 7% polyacrylamide
gels and Tris–glycine running buffer (Bio-Rad, Hercules, CA,
USA) containing 0.2% deoxycholate in the cathode chamber
(Iwamura et al., 2001). The gel was pre-run for 30 min at 40 mA.After clarification by centrifugation at 20,000×g for 10 min, the
lysates were electrophoresed at 25 mA. Following electropho-
resis, proteins were transferred to polyvinylidene difluoride
(PVDF)membranes and analyzedwith antisera specific for IRF3
(Santa Cruz Biotechnology, sc-9082; 1:500). Primary antibodies
were detected using horseradish peroxidase-conjugated second-
ary antibody (1:10,000) and chemiluminescent substrate (Super-
Signal West Pico, Pierce).
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